Breaking News, Collaborations & Alliances

ImmunoGen To Develop Mfg. Process for Genentech

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ImmunoGen, Inc. has entered into an agreement to collaborate with Genentech to create a commercial manufacturing process for Genentech’s trastuzumab-DM1 TAP compound. The two companies have agreed to amend their 2000 agreement that grants Genentech exclusive rights to use ImmunoGen’s TAP technology with therapeutic antibodies to HER2. This amendment increases the total potential milestone payments to ImmunoGen to $44 million and the royalties to ImmunoGen on HER2-targeting TAP compou...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters